Clarivate Expands International Real-World Data Offering with Addition of Techtrials Brazilian Dataset
On November 2, 2020, Clarivate Plc (NYSE:CCC) announced a partnership with Techtrials Pesquisa e Tecnologia Ltda to expand its real-world data (RWD) offerings in Brazil, targeting 80% of the population. This three-year collaboration will allow customers to access the largest integrated RWD database in Brazil, encompassing over 195 million patients. The partnership aims to support various healthcare inquiries, including epidemiological and clinical outcomes, and is expected to enhance decision-making for life science companies given Brazil's growing pharmaceutical market.
- Partnership with Techtrials enhances access to the largest integrated RWD database in Brazil.
- Access to data on over 195 million patients allows for comprehensive healthcare insights.
- Supports an array of healthcare inquiries, boosting decision-making for clients.
- None.
Partnership to provide life science, healthcare and research professionals with comprehensive RWD capturing approximately
LONDON, Nov. 2, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the expansion of international real-world data offerings through its partnership with Techtrials Pesquisa e Tecnologia Ltda (Techtrials), the leading healthcare real-world data (RWD) provider in Brazil. The new partnership will provide customers with comprehensive RWD capturing approximately
As part of the three-year partnership, Clarivate customers can access the largest integrated real-world database in Brazil to address the most pressing questions related to epidemiological, clinical and pharmacoeconomic outcomes. The dataset features in-depth, clinically structured, anonymized data of billions of records with more than 195 million patients in the public and private market as well as claims, electronic medical records, registry and lab data. The comprehensive Techtrials real-world data paired with the expertise, information and insights that power DRG healthcare products and services, will allow global researchers to access, synthesize and analyze critical data.
The Techtrials dataset will be available to life sciences companies internationally, supporting a multitude of end users, to enable deeper insights and delivery of complex and high value use cases. Clients can choose from an array of delivery options depending on their resource needs and expertise, including: commercial targeting; patient population & market sizing; patient journey; therapeutic area assessments; disease burden analysis; health economics and outcomes research and more.
As the world's 11th largest pharmaceutical market, Brazil spends 9.5 percent of GDP on healthcare – providing universal healthcare to its population.1 Multinational pharmaceutical companies continue to invest and expand operations in Brazil, with market researchers anticipating spending to increase at a compound annual growth rate of
Ken McLaren, SVP & GM of Data, Analytics and Insights for Clarivate, said: "We appreciate the complexity of healthcare and the diversity of decisions its leaders must make, especially in an international context. We look forward to partnering with an organization like Techtrials to help our customers understand and drive decision-making with confidence in the high growth, high interest Brazilian market."
Douglas Andreas Valverde, CEO, Techtrials, said: "As a regional innovation leader for data solutions and real-world evidence, we offer a unique mix of capabilities and proprietary technology, providing valuable clinical and real-world evidence insights to support the efforts of pharmaceutical, healthcare and government agencies. We are proud to partner with Clarivate to reach international industry stakeholders who need to act and make critical decisions in their daily operations."
The Brazilian RWD offering features insights, including: new professionals per institution; variation of patients per period; procedures; workload by institution; comprehensive disease, epidemiology and market knowledge; drug use by specialty; outcomes, hospitalizations, surgeries and sub-procedures; hospital and comorbidities and more. The incorporation of Techtrials data further reinforces the expertise provided by Clarivate to support customers across the entire drug, device and medical technology lifecycles.
To learn more, visit https://clarivate.com/drg/real-world-data.
About Clarivate
Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.
Media Contact
Catherine Daniel
media.enquiries@clarivate.com
1National Health Account (NHA) Indicators 2020. Source: Global Health Expenditure Database (GHED) of the World Health Organization.
2"Brazil: Commercialization Outlook, Global Market Access Solutions" 2020. Source: DRG, part of Clarivate
View original content to download multimedia:http://www.prnewswire.com/news-releases/clarivate-expands-international-real-world-data-offering-with-addition-of-techtrials-brazilian-dataset-301164471.html
SOURCE Clarivate Plc
FAQ
What is the new partnership announced by Clarivate on November 2, 2020?
How much of the Brazilian population will be covered by the new RWD partnership?
What key insights will the Techtrials dataset provide for life sciences companies?
What is the significance of Brazil's pharmaceutical market for Clarivate?
What type of data will be available from the partnership between Clarivate and Techtrials?
